Actively Recruiting

All Genders
ID02454569

Vicente Ferrer HIV Cohort Study

Led by Rural Development Trust Hospital · Updated on 2023-03-29

30000

Participants Needed

1

Research Sites

17 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting a long-term prospective study called the Vicente Ferrer HIV Cohort Study (VFHCS) to understand HIV and related health issues in a rural area of India with high HIV prevalence. The study aims to describe how HIV spreads, its social and medical impact, and the effectiveness of health programs in real-world conditions. It focuses on various aspects including opportunistic infections like tuberculosis, life expectancy, treatment effects, and non-communicable diseases in people living with HIV. The VFHCS collects routine clinical data from HIV-infected patients attending Bathalapalli Rural Development Trust Hospital since September 2009. Data include information on HIV transmission, risk factors, treatments such as antiretroviral therapy, laboratory tests like CD4 counts, and medical diagnoses. The study continues to gather data to evaluate trends, treatment toxicity, and program effectiveness over time in this rural setting. Participants are followed over many years, with researchers tracking mortality and health outcomes from the time of HIV diagnosis, using time-to-event methods for up to 30 years. The study collects social, medical, and laboratory data regularly to monitor disease progression, treatment response, and retention in care. This long-term monitoring helps to understand factors influencing survival and health among rural Indian patients living with HIV.

CONDITIONS

Brief Title

Vicente Ferrer HIV Cohort Study

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Positive serology for HIV
Not Eligible

You will not qualify if you...

  • Refuse to consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Monitoring

Duration - Up to 30 years from HIV diagnosis

Participants who have tested positive for HIV are observed with routine clinical data collected prospectively, including medical treatments, laboratory tests, and standardized diagnoses.

Trial Site Locations

Total: 1 location

1

RDT Hospital

Battalapalli, Andhra Pradesh, India, 515661

Actively Recruiting

Loading map...

Research Team

G

Gerardo Alvarez-Uria

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

#AWARE.HIV Europe: Supporting Healthcare Professionals to Fi...

HIV Infection

Actively Recruiting

28 locations

1MoreStep: Pilot Trial of an Intervention to Increase HIV Ca...

Violence, Domestic

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India.

Gerardo Alvarez-Uria, Manoranjan Midde, Raghavakalyam Pakam...

https://pubmed.ncbi.nlm.nih.gov/24470926

Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting.

Gerardo Alvarez-Uria, Praveen Kumar Naik, Rhagavakalyan Pakam...

https://pubmed.ncbi.nlm.nih.gov/22487689

Factors Associated with Late Presentation of HIV and Estimation of Antiretroviral Treatment Need according to CD4 Lymphocyte Count in a Resource-Limited Setting: Data from an HIV Cohort Study in India.

Gerardo Alvarez-Uria, Manoranjan Midde, Raghavakalyan Pakam...

https://pubmed.ncbi.nlm.nih.gov/22611389

Effect of Formula Feeding and Breastfeeding on Child Growth, Infant Mortality, and HIV Transmission in Children Born to HIV-Infected Pregnant Women Who Received Triple Antiretroviral Therapy in a Resource-Limited Setting: Data from an HIV Cohort Study in India.

Gerardo Alvarez-Uria, Manoranjan Midde, Raghavakalyan Pakam...

https://pubmed.ncbi.nlm.nih.gov/22701801

An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype.

Andrew D Revell, Dechao Wang, Robin Wood...

https://pubmed.ncbi.nlm.nih.gov/27330070

Mortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weighting.

Gerardo Alvarez-Uria, Manoranjan Midde, Praveen K Naik

https://pubmed.ncbi.nlm.nih.gov/27231666

Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis.

Gerardo Alvarez-Uria, Manoranjan Midde, Raghavakalyan Pakam...

https://pubmed.ncbi.nlm.nih.gov/26448766

Adding Streptomycin to an Intensified Regimen for Tuberculous Meningitis Improves Survival in HIV-Infected Patients.

Gerardo Alvarez-Uria, Raghavakalyan Pakam, Manoranjan Midde...

https://pubmed.ncbi.nlm.nih.gov/26347376

Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India.

Gerardo Alvarez-Uria, Raghavakalyan Pakam, Manoranjan Midde...

https://pubmed.ncbi.nlm.nih.gov/25499123

Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.

Gerardo Alvarez-Uria, Raghavakalyan Pakam, Praveen Kumar Naik...

https://pubmed.ncbi.nlm.nih.gov/25232730